EKF Diagnostics showcases PointMan at Tri-Con 2014

EKF Diagnostics is showcasing its groundbreaking new PointMan product offering at Tri-Con 2014, an industry conference taking place in San Francisco this week.

Attendees of the event – which runs from February 10th to 14th 2014 – will be able to discuss the benefits of the DNA enrichment technology, which uses real-time polymerase chain reaction techniques to reliable and sensitively detect cancer-related mutations.

It is fully compatible with industry standard instruments and DNA extraction methods, offering highly specific and efficient performance in amplifying the target sequence, while simultaneously suppressing amplification of the wild-type.

As such, it is able to provide samples that are effectively enriched for the mutation, providing industry-leading sensitivity across a wide variety of sample types, including whole blood.

Andrew Webb, chief executive officer of EKF Molecular Diagnostics, said: "Tri-Con 2014 provides an ideal platform to feature our growing range of products and technologies developed to meet an increasing demand for superior sensitivity and specificity in molecular diagnostics."

Last month, it was announced that PointMan has been used by Swansea University to successfully identify gene mutations associated with response to drug treatment among metastatic melanoma patients.